Hyderabad, India, 2013 –Croissance Clinical Research, has collaborated with Cipla Ltd to offer its end to end clinical research services. Croissance will be indulged in providing services like Clinical Operations, Data Management, Biostatistics, Medical Writing and Quality Assurance.
Cipla is a global pharmaceutical company whose goal is to ensure that no patient shall be denied access to high quality & affordable medicine and support.
Cipla is a pioneer in API manufacturing in India for over 5 decades, Cipla currently manufactures more than 200 generic and complex APIs. Cipla APIs cover a broad spectrum of therapeutic categories that are supplied to some of the major formulation players in the pharmaceutical industry globally – over 350 Drug Master Files (DMF) and 70 Certificate of suitability of Monographs of the European Pharmacopoeia (CEPs).
The company focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
Almost 55% of its overall income from its operations come from outside India. It has 5,500 registered products in various countries. The company also provides consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipment. It has a presence across 170 countries with manufacturing units approved by regulatory authorities like USFDA, WHO–Canada and MHRA–UK, among others. The company won the Forbes Asia’s Best Company under a Billion List from Forbes Magazine. Cipla also won the Most Profitable Company overall among those Under a Billion in the Region among Top 200 Small and Mid-Size companies? from Forbes Magazine.